In preclinical studies, monotherapy with bintrafusp alfa was shown to effectively trap TGF-β and bind PD-L1, resulting in decreased tumor burden and prolonged survival.213,214 Furthermore, treatment with bintrafusp alfa had superior anti-tumor activity than treatment with either anti-PD-L1 or TGF-β, highlighting the importance of co-targeting these two inhibitory molecules. The gene discussed is TGFB1; the disease is neoplasm.